Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases.
canine
octreotide
protein-losing enteropathy
treatment
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
12
06
2023
accepted:
17
11
2023
medline:
1
12
2023
pubmed:
1
12
2023
entrez:
1
12
2023
Statut:
aheadofprint
Résumé
More than 50% of dogs with protein-losing enteropathy (PLE) fail to respond to standard therapies. Octreotide, a somatostatin analogue, is used in cases of intestinal lymphangiectasia (IL) in humans with some success. Describe the use of octreotide in dogs with PLE including reason for and details of prescription, adverse effects, and apparent response. Eighteen dogs with PLE, 13 with histopathology available. Ninety-two percent (12/13) had IL diagnosed on biopsy. All 13 dogs had intestinal inflammatory infiltrates noted. Multicenter, retrospective, descriptive study. Cases were volunteered for inclusion by individual attending veterinarians who reported the use of octreotide in cases of PLE. In 16/18 (89%) cases octreotide was prescribed to PLE dogs with a clinical suspicion or confirmed diagnosis of IL that were refractory to standard therapies. Median serum albumin at the time of octreotide prescription was 1.7 g/dL (range, 1.0-3.1 g/dL). The median dose of octreotide prescribed was 20 μg/kg, SQ, daily with a range of 4-39 μg/kg, SQ, daily. Adverse effects were noted in 3/18 (17%, 95% CI [4%, 41%]) of dogs; discontinuation of the drug was necessary in 1 dog. Improvement in clinical signs was noted in 6/12 (50%, 95% CI [21%, 79%]). Octreotide was most commonly prescribed to dogs with PLE and suspected or confirmed IL that had failed to respond to standard therapies. Though a benefit to PLE dogs cannot be confirmed, octreotide was well tolerated by the majority of dogs at the doses prescribed in this study.
Sections du résumé
BACKGROUND
BACKGROUND
More than 50% of dogs with protein-losing enteropathy (PLE) fail to respond to standard therapies. Octreotide, a somatostatin analogue, is used in cases of intestinal lymphangiectasia (IL) in humans with some success.
OBJECTIVES
OBJECTIVE
Describe the use of octreotide in dogs with PLE including reason for and details of prescription, adverse effects, and apparent response.
ANIMALS
METHODS
Eighteen dogs with PLE, 13 with histopathology available. Ninety-two percent (12/13) had IL diagnosed on biopsy. All 13 dogs had intestinal inflammatory infiltrates noted.
METHODS
METHODS
Multicenter, retrospective, descriptive study. Cases were volunteered for inclusion by individual attending veterinarians who reported the use of octreotide in cases of PLE.
RESULTS
RESULTS
In 16/18 (89%) cases octreotide was prescribed to PLE dogs with a clinical suspicion or confirmed diagnosis of IL that were refractory to standard therapies. Median serum albumin at the time of octreotide prescription was 1.7 g/dL (range, 1.0-3.1 g/dL). The median dose of octreotide prescribed was 20 μg/kg, SQ, daily with a range of 4-39 μg/kg, SQ, daily. Adverse effects were noted in 3/18 (17%, 95% CI [4%, 41%]) of dogs; discontinuation of the drug was necessary in 1 dog. Improvement in clinical signs was noted in 6/12 (50%, 95% CI [21%, 79%]).
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
Octreotide was most commonly prescribed to dogs with PLE and suspected or confirmed IL that had failed to respond to standard therapies. Though a benefit to PLE dogs cannot be confirmed, octreotide was well tolerated by the majority of dogs at the doses prescribed in this study.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Références
Dossin O, Lavoué R. Protein-losing enteropathies in dogs. Vet Clin North Am Small Anim Pract. 2011;41(2):399-418.
Craven MD, Washabau RJ. Comparative pathophysiology and management of protein-losing enteropathy. J Vet Intern Med. 2019;33(2):383-402.
Littman MP, Dambach DM, Vaden SL, Giger U. Familial protein-losing enteropathy and protein-losing nephropathy in soft coated wheaten terriers: 222 cases (1983-1997). J Vet Intern Med. 2000;14(1):68-80.
Allenspach K, Lomas B, Wieland B, et al. Evaluation of perinuclear anti-neutrophilic cytoplasmic autoantibodies as an early marker of protein-losing enteropathy and protein-losing nephropathy in soft coated wheaten terriers. Am J Vet Res. 2008;69(10):1301-1304.
Simmerson SM, Armstrong PJ, Wünschmann A, Jessen CR, Crews LJ, Washabau RJ. Clinical features, intestinal histopathology, and outcome in protein-losing enteropathy in Yorkshire terrier dogs. J Vet Intern Med. 2014;28(2):331-337.
Jablonski Wennogle SA, Priestnall SL, Webb CB. Histopathologic characteristics of intestinal biopsy samples from dogs with chronic inflammatory enteropathy with and without hypoalbuminemia. J Vet Intern Med. 2017;31(2):371-376.
Jablonski Wennogle SA, Priestnall SL, Suárez-Bonnet A, Webb CB. Comparison of clinical, clinicopathologic, and histologic variables in dogs with chronic inflammatory enteropathy and low or normal serum 25-hydroxycholecalciferol concentrations. J Vet Intern Med. 2019;33(5):1995-2004.
Heilmann RM, Parnell NK, Grützner N, et al. Serum and fecal canine α1-proteinase inhibitor concentrations reflect the severity of intestinal crypt abscesses and/or lacteal dilation in dogs. Vet J. 2016;207:131-139.
Rossi G, Cerquetella M, Antonelli E, et al. The importance of histologic parameters of lacteal involvement in cases of canine lymphoplasmacytic enteritis. Gastroenterol Hepatol Bed Bench. 2015;8(1):33-41.
Campbell RS, Brobst D, Bisgard G. Intestinal lymphangiectasia in a dog. J Am Vet Med Assoc. 1968;153(8):1051-1054.
Jablonski SA. Pathophysiology, diagnosis, and management of canine intestinal lymphangiectasia: a comparative review. Animals (Basel). 2022;12(20):2791.
Jablonski Wennogle SA, Stockman J, Webb CB. Prospective evaluation of a change in dietary therapy in dogs with steroid-resistant protein-losing enteropathy. J Small Anim Pract. 2021;62(9):756-764.
Allenspach K, Iennarella-Servantez C. Canine protein losing enteropathies and systemic complications. Vet Clin North Am Small Anim Pract. 2021;51(1):111-122.
Prasad D, Srivastava A, Tambe A, Yachha SK, Sarma MS, Poddar U. Clinical profile, response to therapy, and outcome of children with primary intestinal lymphangiectasia. Dig Dis. 2019;37(6):458-466.
Ballinger AB, Farthing MJ. Octreotide in the treatment of intestinal lymphangiectasia. Eur J Gastroenterol Hepatol. 1998;10(8):699-702.
Bac DJ, Van Hagen PM, Postema PT, ten Bokum AM, Zondervan PE, van Blankenstein M. Octreotide for protein-losing enteropathy with intestinal lymphangiectasia. Lancet. 1995;345(8965):1639.
Al Sinani S, Rawahi YA, Abdoon H. Octreotide in Hennekam syndrome-associated intestinal lymphangiectasia. World J Gastroenterol. 2012;18(43):6333-6337.
Alshikho MJ, Talas JM, Noureldine SI, et al. Intestinal lymphangiectasia: insights on management and literature review. Am J Case Rep. 2016;17:512-522.
Filik L, Oguz P, Koksal A, Koklu S, Sahin B. A case with intestinal lymphangiectasia successfully treated with slow-release octreotide. Dig Liver Dis. 2004;36(10):687-690.
Kuroiwa G, Takayama T, Sato Y, et al. Primary intestinal lymphangiectasia successfully treated with octreotide. J Gastroenterol. 2001;36(2):129-132.
Sari S, Baris Z, Dalgic B. Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment? J Pediatr Gastroenterol Nutr. 2010;51(4):454-457.
Suehiro K, Morikage N, Murakami M, Yamashita O, Hamano K. Late-onset primary intestinal lymphangiectasia successfully managed with octreotide: a case report. Ann Vasc Dis. 2012;5(1):96-99.
Reeves LA, Anderson KM, Luther JK, Torres BT. Treatment of idiopathic chylothorax in dogs and cats: a systematic review. Vet Surg. 2020;49(1):70-79.
Robben JH, van den Brom WE, Mol JA, van Haeften TW, Rijnberk A. Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma. Res Vet Sci. 2006;80(1):25-32.
Kim S, Hosoya K, Takagi S, Okumura M. Treatment of gastrin-secreting tumor with sustained-release octreotide acetate in a dog. J Am Anim Hosp Assoc. 2015;51(6):407-412.
Myers-Nodes J, Mazepa ASW. Combined surgical and medical management of a cat with gastrinoma. J Small Anim Pract. 2022;63(8):632-634.
Laflamme D. Development and validation of a body condition score system for dogs. Canine Pract. 1997;22(4):10-15.
Freeman LM, Michel KE, Zanghi BM, Vester Boler BM, Fages J. Evaluation of the use of muscle condition score and ultrasonographic measurements for assessment of muscle mass in dogs. Am J Vet Res. 2019;80(6):595-600.
Troskot R, Jurčić D, Bilić A, Gomerčić Palčić M, Težak S, Brajković I. How to treat an extensive form of primary intestinal lymphangiectasia? World J Gastroenterol. 2015;21(23):7320-7325.
Märki F. Effect of somatostatin on intestinal absorption of nutrients the rat. Regul Pept. 1981;2(6):371-381.
Nakabayashi H, Sagara H, Usukura N, et al. Effect of somatostatin on the flow rate and triglyceride levels of thoracic duct lymph in normal and vagotomized dogs. Diabetes. 1981;30(5):440-445.
Markham KM, Glover JL, Welsh RJ, Lucas RJ, Bendick PJ. Octreotide in the treatment of thoracic duct injuries. Am Surg. 2000;66(12):1165-1167.
Collard JM, Laterre PF, Boemer F, Reynaert M, Ponlot R. Conservative treatment of postsurgical lymphatic leaks with somatostatin-14. Chest. 2000;117(3):902-905.
Lamberts SWJ, Hofland LJ. Anniversary review: octreotide, 40 years later. Eur J Endocrinol. 2019;181(5):R173-R183.
Procoli F, Mõtsküla PF, Keyte SV, Priestnall S, Allenspach K. Comparison of histopathologic findings in duodenal and ileal endoscopic biopsies in dogs with chronic small intestinal enteropathies. J Vet Intern Med. 2013;27(2):268-274.
Casamian-Sorrosal D, Willard MD, Murray JK, Hall EJ, Taylor SS, Day MJ. Comparison of histopathologic findings in biopsies from the duodenum and ileum of dogs with enteropathy. J Vet Intern Med. 2010;24(1):80-83.